Topics
bladder cancerDisease
Assessment of ex-vivoefficacy of immunotherapeutic agents in intermediate-risk and high-risknon-muscle invasive bladder cancer</p
OBJECTIVES: To study the diagnostic performance of the ImmunoCyt test in patients in follow-up for s...
Background: Despite extensive research to identify biomarkers of response in patients with non-muscl...
Radical cystectomy is the gold standard treatment for muscle invasive bladder cancer, but some patie...
Assessment of ex-vivoefficacy of immunotherapeutic agents in intermediate-risk and high-risknon-musc...
Purpose: To investigate the ex-vivo efficacy of immunotherapeutics and chemotherapeutics in bladder ...
Combining immune checkpoint inhibitors with other treatment modalities may lead to the development o...
INTRODUCTION/BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) has a strong tendency to recur d...
3si: Predicting response to definitive treatmentsis a fascinating challenge which develops throughth...
Aim This narrative review describes current guidelines for treating NMIBC, provides an overview of t...
Objective: to carry out the comparative efficacy evaluation of various immunohistochemical markers i...
Use of immunotherapy in treatment of muscle-invasive bladder cancer remains the most promising metho...
Introduction: Approximately 70% of bladder cancers are non-muscle-invasive (NMIBC), and respond well...
Purpose: Bladder cancer is the 13th most common cause of cancer death with the highest lifetime cost...
Immunotherapy, in the form of immune checkpoint inhibitors (ICI), has shown activity in metastatic u...
International audienceWith the mechanistic understanding of immune checkpoints and success in checkp...
OBJECTIVES: To study the diagnostic performance of the ImmunoCyt test in patients in follow-up for s...
Background: Despite extensive research to identify biomarkers of response in patients with non-muscl...
Radical cystectomy is the gold standard treatment for muscle invasive bladder cancer, but some patie...
Assessment of ex-vivoefficacy of immunotherapeutic agents in intermediate-risk and high-risknon-musc...
Purpose: To investigate the ex-vivo efficacy of immunotherapeutics and chemotherapeutics in bladder ...
Combining immune checkpoint inhibitors with other treatment modalities may lead to the development o...
INTRODUCTION/BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) has a strong tendency to recur d...
3si: Predicting response to definitive treatmentsis a fascinating challenge which develops throughth...
Aim This narrative review describes current guidelines for treating NMIBC, provides an overview of t...
Objective: to carry out the comparative efficacy evaluation of various immunohistochemical markers i...
Use of immunotherapy in treatment of muscle-invasive bladder cancer remains the most promising metho...
Introduction: Approximately 70% of bladder cancers are non-muscle-invasive (NMIBC), and respond well...
Purpose: Bladder cancer is the 13th most common cause of cancer death with the highest lifetime cost...
Immunotherapy, in the form of immune checkpoint inhibitors (ICI), has shown activity in metastatic u...
International audienceWith the mechanistic understanding of immune checkpoints and success in checkp...
OBJECTIVES: To study the diagnostic performance of the ImmunoCyt test in patients in follow-up for s...
Background: Despite extensive research to identify biomarkers of response in patients with non-muscl...
Radical cystectomy is the gold standard treatment for muscle invasive bladder cancer, but some patie...
Add to ORKG